Already a member? Become a member Register
PCSK9 Forum

rss LinkedIn News
rss LinkedIn Latest News Updates

About the PCSK9 Education and Research Forum

PCSK9 Education and Research Forum is the independent resource on PCSK9 science and its translation into critically important new treatments to lower low density lipoprotein cholesterol (LDL-C), which promise to transform the prognosis of millions of patients with hypercholesterolaemia (cholesterol disorders), accelerated atherosclerotic vascular heart disease and a high risk of premature cardiovascular (CV) death and disability.
Aims & ObjectivesMission StatementEditorial BoardPartnership & OutreachForthcoming Meetings
What will members gain?
Most viewed
Most viewed

Lipoprotein(a) – does it matter when LDL cholesterol is low?

Lipoprotein(a) is now recognised as an independent risk factor for cardiovascualr disease.

But is it also relevant to consider lipoprotein(a) when LDL cholesterol is low?

Prof. Anthony S Wierzbicki, Guy’s and St Thomas’ Hospitals, London, UK discusses the evidence.

Read the report

Hot Topics

Guidance needed on LDL lowering in very high-risk patients

Do high and very high-risk patients at guideline-recommended goal gain more benefit from further lowering LDL cholesterol levels? PCSK9 Forum Editor Professor John Chapman (UPMC-Sorbonne, Director Emeritus, INSERM, Paris, France), discusses.

Read the report

Video: Impetus to change LDL-C goal from FOURIER
Watch the video

From the Editors

The lipoprotein(a) – LDL cholesterol conundrumThe lipoprotein(a) – LDL cholesterol conundrum

Frederick J. Raal

Professor Derick Raal (University of the Witwatersrand, Johannesburg, South Africa) discusses issues related to lowering elevated lipoprotein(a): is it beneficial when LDL cholesterol is low?

Read the article

Lowering lipoprotein(a) when LDL-C is very low

Watch the video

Lowering lipoprotein(a) for clinical benefit

Watch the video

How much lipoprotein(a) lowering for CV benefit?

Read the report

Meet our Editorial Board

View all our Editorial Board Prof John ChapmanResearch Professor at the University of Pierre and Marie Curie Prof Henry GinsbergDirector, Irving Institute for Clinical and Translational Research Dr Michel FarnierClinician based at Point Medical, Dijon, France Prof Frederick RaalDirector, Carbohydrate & Lipid Metabolism Research Unit Prof Anthony WierzbickiConsultant in Metabolic Medicine/Chemical Pathology